STERIS plc: Fiscal 2024 Third-Quarter 10-Q Summary
Business Context and Reporting Period
STERIS plc is a global provider of infection-prevention products and services serving healthcare, medical-device, pharmaceutical, life-sciences, and dental customers. Reportable segments are Healthcare, Applied Sterilization Technologies (AST), Life Sciences, and Dental. This Form 10-Q covers the three and nine months ended December 31, 2023, the third quarter and first nine months of fiscal 2024. The interim financial statements are unaudited and were reviewed by Ernst & Young LLP.
Key Financial Metrics
| Metric | Q3 FY2024 | Q3 FY2023 | 9M FY2024 | 9M FY2023 |
|---|---|---|---|---|
| Revenue | $1,395.6 million | $1,216.0 million | $4,022.5 million | $3,573.0 million |
| Revenue growth | 14.8% | — | 12.6% | — |
| Gross profit | $602.6 million | $521.5 million | $1,769.6 million | $1,571.6 million |
| Gross margin | 43.2% | 42.9% | 44.0% | 44.0% |
| Operating income | $216.2 million | $190.8 million | $590.9 million | $42.8 million |
| Net income attributable to shareholders | $140.7 million | $123.8 million | $379.6 million | $(80.2) million |
| Diluted EPS | $1.42 | $1.24 | $3.82 | $(0.80) |
| Operating cash flow | Not separately provided | Not separately provided | $718.5 million | $541.1 million |
| Free cash flow | Not separately provided | Not separately provided | $457.0 million | $262.8 million |
Q3 revenue growth reflected higher volume, pricing, and contributions from the BD surgical-instrumentation asset acquisition. Product revenue increased 18.5% to $804.8 million, while service revenue increased 10.0% to $590.9 million. Capital-equipment revenue increased 22.1% in the quarter and 20.0% for the first nine months.
Q3 operating margin was approximately 15.5%, compared with approximately 15.7% in the prior-year quarter. The nine-month operating margin was approximately 14.7%, versus approximately 1.2% in the prior-year period, primarily because the prior year included a $490.6 million Dental goodwill impairment charge.
Segment Performance
| Segment | Q3 Revenue | Q3 Growth | 9M Revenue | 9M Growth |
|---|---|---|---|---|
| Healthcare | $916.2 million | 19.1% | $2,605.2 million | 18.4% |
| AST | $234.9 million | 5.8% | $703.1 million | 4.1% |
| Life Sciences | $146.6 million | 20.9% | $411.1 million | 8.4% |
| Dental | $97.9 million | (5.4%) | $303.2 million | (4.6%) |
- Healthcare operating income increased 27.7% in Q3 and 25.9% for nine months; margins were 24.4% and 24.0%, respectively.
- AST revenue grew modestly, but operating margins declined to 44.8% in Q3 and 46.3% for nine months because higher labor and energy costs and lower productivity outweighed pricing benefits.
- Life Sciences operating income increased 25.4% in Q3 and 5.2% for nine months. Nine-month margin declined to 38.2% from 39.3% because inflation exceeded pricing benefits.
- Dental revenue and operating income declined due to customer inventory destocking and reduced orders from a large customer affected by a cybersecurity incident. Three customers represented approximately 47.5% of Dental revenue in Q3 and 44.5% for nine months.
Material Changes Versus the Prior Comparable Period
- The August 2, 2023 acquisition of certain BD surgical, laparoscopic, and sterilization-container assets cost $539.8 million and was integrated into Healthcare. It was financed with borrowings under the existing credit facility and included an estimated $60.0 million present-value tax benefit related to tax-deductible goodwill.
- Operating income and net income improved sharply for the nine-month period because the prior-year results included the $490.6 million Dental goodwill impairment charge.
- Interest expense increased to $38.9 million in Q3 and $108.2 million for nine months, driven primarily by higher rates and higher floating-rate debt balances.
- Gross margin was slightly higher in Q3 due primarily to pricing, but was unchanged for nine months as pricing and mix benefits were offset by material and labor inflation, productivity pressures, and currency-related effects.
- SG&A increased 18.1% in Q3 and 14.3% for nine months, reflecting higher compensation, incentive compensation, dealer incentives, professional fees, bad-debt expense, and travel costs.
Cash Flow, Debt, and Liquidity
- Cash and cash equivalents were $195.6 million at December 31, 2023, compared with $208.4 million at March 31, 2023.
- Total debt was $3.31 billion at December 31, 2023, up from $3.08 billion at March 31, 2023. Long-term indebtedness was $3.23 billion and short-term indebtedness was $78.4 million.
- The debt-to-total-capital ratio was 34.0% at December 31, 2023, compared with 33.6% at March 31, 2023.
- Net cash used in investing activities was $791.8 million, including $539.8 million for the BD acquisition and $268.8 million of capital expenditures.
- Net cash provided by financing activities was $58.6 million, including $265.5 million of net credit-facility borrowings, $45.0 million of term-loan repayments, and $149.2 million of dividends paid.
- Outstanding borrowings under the credit agreement were $570.0 million, with $11.6 million of letters of credit outstanding. Commercial commitments were approximately $113.0 million.
- Management expects existing cash and operating cash flow to fund near-term capital expenditures and other liquidity needs, but states that additional borrowing or equity financing could be required if available sources are insufficient.
Outlook, Risks, Contingencies, and Unusual Items
The filing does not provide a clear quantitative full-year revenue or earnings guidance update. Management attributes current growth to volume, pricing, acquisitions, and demand in healthcare and life-sciences markets, while noting inflation, productivity, customer inventory management, and supply-chain conditions as pressures.
- The IRS issued two November 2023 Notices of Deficiency concerning deemed dividend inclusions and withholding tax for 2018. The asserted cumulative tax liability is approximately $50.0 million. STERIS is contesting the notices in U.S. Tax Court and has not recorded reserves. An unfavorable outcome is not expected to materially affect consolidated financial position but could materially affect a single period's results and cash flows.
- Legal proceedings, product-liability claims, regulatory matters, government investigations, tax matters, and other claims are ongoing in the ordinary course. Management believes probable and estimable losses are adequately reserved and that current matters are not expected to have a material adverse effect overall, although outcomes remain uncertain.
- Key operating risks include inflation and margin pressure, raw-material availability and pricing, foreign-currency exposure, interest-rate risk, regulatory and product-approval requirements, cybersecurity events affecting customers or operations, acquisition integration, reduced demand, supply-chain disruption, geopolitical events, tax-law changes, and elevated indebtedness.
- STERIS held foreign-currency forward contracts and nickel commodity swaps as of December 31, 2023. The derivatives are not used for speculative purposes, but their accounting treatment may create earnings volatility.
- No goodwill impairment indicators were identified as of December 31, 2023. The BD purchase-price allocation remained preliminary.
- The company authorized a $500 million share-repurchase program in May 2023 but made no purchases under the program during the first nine months of fiscal 2024. It repurchased $11.4 million of shares in connection with share-based compensation programs.
Most Important Facts for Investors to Verify
- Whether Healthcare growth and the BD acquisition produce the expected revenue, cost, and synergy benefits.
- Whether AST and Life Sciences margins recover from labor, energy, inflation, and productivity pressures.
- Whether Dental customer destocking, customer concentration, and cybersecurity-related disruption continue to affect revenue.
- The pace of debt reduction, floating-rate exposure, interest expense, and remaining liquidity after the BD acquisition.
- The status and potential cash impact of the approximately $50 million IRS tax dispute.
- Whether pricing continues to offset inflation and whether gross-margin performance improves beyond the reported 44.0% nine-month level.
- The absence of quantitative fiscal-year guidance in this filing and the need to verify subsequent earnings releases for updated outlook information.